November 14, 2023Journal of Clinical Oncology91 citationsOpen Access

Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial

Key points are not available for this paper at this time.

Olaparib improved PFS and OS across subgroups of BRCA1/2mut #prostatecancer patients in the PROFOUND phase III trial.

Demander à l'IA

Bookmark

View Full Paper

Cite This Study

Mateo et al. (Tue,) studied this question.

Demander à l'IA

Bookmark

View Full Paper